PCV13 in Adults Under 65 With Diabetes May Avert Pneumonia Hospitalizations

PCV13 vaccination in this population could avert 24,638 to 44,506 hospitalizations.
PCV13 vaccination in this population could avert 24,638 to 44,506 hospitalizations.
This article is part of MPR's coverage of IDWeek 2018, taking place in San Francisco, CA. Our on-site staff will be reporting on the latest breaking research and clinical advances in infectious diseases. Check back regularly for highlights from IDWeek 2018.

SAN FRANCISCO — Use of 13-valent conjugate pneumococcal vaccination (PCV13) in adults with diabetes age <65 years could reduce a substantial number of pneumonia hospitalizations, according to a study presented at IDWeek 2018 , held October 3 to 7, 2018, in San Francisco, California.

Jose Suaya, MD, PhD, and colleagues sought to evaluate whether PCV13 could be recommended for younger adults with diabetes to avert hospitalization for pneumonia. The researchers considered multiple scenarios depending on vaccine efficacy/effectiveness estimates and estimated the number of the following:

  • Hospitalizations averted as the product of target population size
  • Incidence of all-cause community-associated pneumonia (CAP),
  • Proportion of CAP that is PCV13 type
  • PCV13 effectiveness
  • Duration of protection for PCV13 over a 5-year time period
  • Number-needed-to-vaccinate for each scenario

The study showed that approximately 15 million adults age <65 years in the United States have diabetes, which accounts for 250,000 hospitalizations for CAP annually. The results showed that PCV13 vaccination in this population could avert 24,638-44,506 hospitalizations and 206,955 to 373,854 hospital days over a 5-year period and the number needed to vaccinate to avert 1 hospitalization and 1 hospital day were 344 to 622 and 41 to 74, respectively.

Related Articles

The study authors concluded that because the number needed to vaccinate to avert one case of CAP in younger patients with diabetes was similar to the number shown in current guidelines for older patients, PCV13 vaccination of younger patients with diabetes might reduce significantly the number of individuals who require hospitalization for pneumonia.

Visit MPR's conference section for continuous coverage live from IDWeek 2018.

Reference

Suaya J, Gessner BD, Chilson E, et al. Pneumonia hospitalizations averted with 13-valent pneumococcal conjugate vaccination of adults aged 18-64 years with diabetes in the United States. Presented at: IDWeek 2018; October 3-7, 2018; San Diego, CA. Abstract 1442.